BridgeBio reports infigratinib trial data on sleep apnea, ear infections

September 9, 2026 4:00 AM

BridgeBio Pharma (Nasdaq: BBIO) presented exploratory data from its Phase 3 PROPEL 3 trial of oral infigratinib in children with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found